Articles related to LIPID MANAGEMENT

“Pelacarsen lowered lipoprotein(a) to less than 50 mg/dL in 98% of participants, but levels rebounded after 16 weeks.”

The FDA’s Class II designation indicates that exposure or usage of ‘a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.’

“There are cholesterol quacks out there—some as smart as they are duplicitous—telling lies about cholesterol and statins, talking thousands of people into ignoring their dangerously high cholesterol.”

“Our findings highlight that daily diet matters not only for cancer risk but also for how the disease progresses once it has developed… reducing sugary drinks, targeting SORD or repurposing statins may benefit patients with colorectal cancer.” – Jihye Yun, Lead Researcher

“The main scenario that prompts me to use apoB is when a patient’s traditional lipid panel values are either normal, or even slightly abnormal, but have discrepancy with the quality/quantity of their other comorbid problems.” — Austin Shuxiao, MD

Triple therapy was linked with slower decline of overall cognition, particularly in semantic and working memory, and showed lower odds of atherosclerosis, reduced AD pathology, and fewer protein buildups.